Literature DB >> 32014991

Genome-wide siRNA screening reveals that DCAF4-mediated ubiquitination of optineurin stimulates autophagic degradation of Cu,Zn-superoxide dismutase.

Kengo Homma1,2, Hiromitsu Takahashi3, Naomi Tsuburaya3, Isao Naguro3, Takao Fujisawa3, Hidenori Ichijo3.   

Abstract

Cu, Zn superoxide dismutase (SOD1) is one of the genes implicated in the devastating neurodegenerative disorder amyotrophic lateral sclerosis (ALS). Although the precise mechanisms of SOD1 mutant (SOD1mut)-induced motoneuron toxicity are still unclear, defects in SOD1 proteostasis are known to have a critical role in ALS pathogenesis. We previously reported that the SOD1mut adopts a conformation that exposes a Derlin-1-binding region (DBR) and that DBR-exposed SOD1 interacts with Derlin-1, leading to motoneuron death. We also found that an environmental change, i.e. zinc depletion, induces a conformational change in WT SOD1 (SOD1WT) to the DBR-exposed conformation, suggesting the presence of an equilibrium state between the DBR-masked and DBR-exposed states even with SOD1WT Here, we conducted a high-throughput screening based on time-resolved FRET to further investigate the SOD1WT conformational change, and we used a genome-wide siRNA screen to search for regulators of SOD1 proteostasis. This screen yielded 30 candidate genes that maintained an absence of the DBR-exposed SOD1WT conformation. Among these genes was one encoding DDB1- and CUL4-associated factor 4 (DCAF4), a substrate receptor of the E3 ubiquitin-protein ligase complex. Of note, we found that DCAF4 mediates the ubiquitination of an ALS-associated protein and autophagy receptor, optineurin (OPTN), and facilitates autophagic degradation of DBR-exposed SOD1. In summary, our screen identifies DCAF4 as being required for proper proteostasis of DBR-exposed SOD1, which may have potential relevance for the development of therapies for managing ALS.
© 2020 Homma et al.

Entities:  

Keywords:  DDB1 and CUL4 associated factor 4 (DCAF4); amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease); autophagy; genome-wide siRNA screen; protein aggregation; protein misfolding; proteostasis; superoxide dismutase 1 (SOD1)

Mesh:

Substances:

Year:  2020        PMID: 32014991      PMCID: PMC7062173          DOI: 10.1074/jbc.RA119.010239

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol.

Authors:  Yihong Ye; Yoko Shibata; Chi Yun; David Ron; Tom A Rapoport
Journal:  Nature       Date:  2004-06-24       Impact factor: 49.962

Review 2.  ALS: a disease of motor neurons and their nonneuronal neighbors.

Authors:  Séverine Boillée; Christine Vande Velde; Don W Cleveland
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

3.  Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth.

Authors:  Philipp Wild; Hesso Farhan; David G McEwan; Sebastian Wagner; Vladimir V Rogov; Nathan R Brady; Benjamin Richter; Jelena Korac; Oliver Waidmann; Chunaram Choudhary; Volker Dötsch; Dirk Bumann; Ivan Dikic
Journal:  Science       Date:  2011-05-26       Impact factor: 47.728

4.  A PP6-ASK3 Module Coordinates the Bidirectional Cell Volume Regulation under Osmotic Stress.

Authors:  Kengo Watanabe; Tsuyoshi Umeda; Kuniyoshi Niwa; Isao Naguro; Hidenori Ichijo
Journal:  Cell Rep       Date:  2018-03-13       Impact factor: 9.423

5.  Toxic mutants in Charcot's sclerosis.

Authors:  D W Cleveland; N Laing; P V Hurse; R H Brown
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

Review 6.  SQSTM1 mutations--bridging Paget disease of bone and ALS/FTLD.

Authors:  Sarah L Rea; Veronika Majcher; Mark S Searle; Rob Layfield
Journal:  Exp Cell Res       Date:  2014-01-30       Impact factor: 3.905

Review 7.  Optineurin in amyotrophic lateral sclerosis: Multifunctional adaptor protein at the crossroads of different neuroprotective mechanisms.

Authors:  Andrea Markovinovic; Raffaello Cimbro; Tereza Ljutic; Jasna Kriz; Boris Rogelj; Ivana Munitic
Journal:  Prog Neurobiol       Date:  2017-04-26       Impact factor: 11.685

8.  The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis.

Authors:  Keiko Imamura; Yuishin Izumi; Akira Watanabe; Kayoko Tsukita; Knut Woltjen; Takuya Yamamoto; Akitsu Hotta; Takayuki Kondo; Shiho Kitaoka; Akira Ohta; Akito Tanaka; Dai Watanabe; Mitsuya Morita; Hiroshi Takuma; Akira Tamaoka; Tilo Kunath; Selina Wray; Hirokazu Furuya; Takumi Era; Kouki Makioka; Koichi Okamoto; Takao Fujisawa; Hideki Nishitoh; Kengo Homma; Hidenori Ichijo; Jean-Pierre Julien; Nanako Obata; Masato Hosokawa; Haruhiko Akiyama; Satoshi Kaneko; Takashi Ayaki; Hidefumi Ito; Ryuji Kaji; Ryosuke Takahashi; Shinya Yamanaka; Haruhisa Inoue
Journal:  Sci Transl Med       Date:  2017-05-24       Impact factor: 17.956

9.  Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.

Authors:  Daryl A Bosco; Gerardo Morfini; N Murat Karabacak; Yuyu Song; Francois Gros-Louis; Piera Pasinelli; Holly Goolsby; Benjamin A Fontaine; Nathan Lemay; Diane McKenna-Yasek; Matthew P Frosch; Jeffrey N Agar; Jean-Pierre Julien; Scott T Brady; Robert H Brown
Journal:  Nat Neurosci       Date:  2010-10-17       Impact factor: 24.884

10.  Astrocytes from familial and sporadic ALS patients are toxic to motor neurons.

Authors:  Amanda M Haidet-Phillips; Mark E Hester; Carlos J Miranda; Kathrin Meyer; Lyndsey Braun; Ashley Frakes; SungWon Song; Shibi Likhite; Matthew J Murtha; Kevin D Foust; Meghan Rao; Amy Eagle; Anja Kammesheidt; Ashley Christensen; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2011-08-10       Impact factor: 54.908

View more
  1 in total

Review 1.  Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.

Authors:  François Le Guerroué; Richard J Youle
Journal:  Cell Death Differ       Date:  2020-11-18       Impact factor: 12.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.